与戒烟药物治疗相关的心血管事件:一个网络元分析
Edward J Mills1, Kristian Thorlund, Shawn Eapen
1Stanford Prevention Research Center, Stanford University, Stanford, CA (E.J.M., K.T., J.J.P.); Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada (E.J.M., S.E., P.W.); and Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada (K.T.).
戒烟药物,如尼古丁替代疗法,布罗和瓦雷尼克林,通常对心血管健康是安全的. 这些疗法并没有增加严重的心血管事件,布普罗甚至显示出保护作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 戒烟显著改善健康和生活质量.
- 建议服用戒烟药物来帮助戒烟.
- 人们对戒烟疗法的潜在心血管风险存在担忧.
研究的目的:
- 评估尼古丁替代疗法,布普罗皮昂和瓦伦尼克林的心血管安全性.
- 为了确定这些戒烟辅助剂是否会增加心血管疾病 (CVD) 事件风险.
主要方法:
- 进行了63项随机临床试验 (RCT) 的网络元分析.
- 综合了关于尼古丁替代疗法,布洛普和瓦雷尼克林报告心血管疾病结局的RCT的数据.
- 搜索包括电子数据库,作者通信和FDA报告.
主要成果:
- 布普罗和瓦雷尼克林并没有显示出整体心血管事件的风险增加.
- 尼古丁替代疗法显示风险较高,主要来自不那么严重的事件.
- 布普罗显示出对重大心血管不良事件的保护作用;瓦雷尼克林和NRT没有显示出重大事件的明显危害.
结论:
- 戒烟疗法,包括尼古丁替代疗法,布罗和瓦伦尼克林,似乎不会增加严重心血管事件的风险.
- 布普罗可能会对主要的不良心血管事件产生保护作用.
相关概念视频
Atherosclerosis III: Management
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Peripheral Artery Disease III: Interprofessional Care
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


